Drug intelligence / Profile preview

GLPG3121

Development stage: Discontinued
Lead developer: Galapagos
Modality: Small Molecules
Administration: Oral

Overview

GLPG3121 is a selective small molecule inhibitor of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), developed by Galapagos for the treatment of inflammatory diseases, particularly with potential application in conditions such as inflammatory bowel disease. The drug was formulated as an oral suspension and underwent Phase 1 clinical trials to assess safety, tolerability, and pharmacokinetics in healthy volunteers. Development was discontinued after Phase 1 studies[1][2][4][5].

Targets

JAK1 (Janus kinase 1)TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on GLPG3121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLPG3121.

Explore the full profile